Mirati’s KRAS Inhibitor Gains Edge On Efficacy, But Safety Trails Amgen’s Competing Drug

Mirati’s adagrasib seems to have better efficacy data while Amgen’s sotorasib has the safety advantage, but oncologists aren’t issuing a verdict yet.